A Phase 1 interventional study of CK-3773274 and Placebo in Obstructive Hypertrophic Cardiomyopathy and Healthy Adult Subjects, sponsored by Corxel Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Corxel Pharmaceuticals · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 3rd registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 18–90
Cytokinetics · Sites in United States, Argentina, Australia and 16 more countries
Ages 18–85
By country, each count listing its studies:
aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2018; this study’s year is marked. 2 started in 2021.
This study's enrollment of 28 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 96 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 4 most frequent:
Corxel Pharmaceuticals is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Corxel Pharmaceuticals has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies testing aficamten in Cardiomyopathy, Hypertrophic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600177Oregon Health and Science UniversityMavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274
Drug: CK-3773274
Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator
Drug: Placebo
Subjects will receive multiple doses of CK-3773274
Drug: CK-3773274
Subjects will receive multiple doses of placebo comparator
Drug: Placebo
CK-3773274- Tablets
Placebo- Tablets
Subject incidence of Adverse Event (AE), Serious Adverse Event (SAE)
Time frame: SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23
Reduced Left Ventricular Ejection Fraction (LVEF)
Time frame: SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23
Cmax of CK-3773274 after single and multiple ascending doses
Time frame: SAD Cohorts: Day-1 - Day10; MD Cohort: Day-1 - Day 23
Ran from Apr 2021 to primary completion in Aug 2021, 3 months.
Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aficamten
Cardiomyopathy, Hypertrophic →
Corxel Pharmaceuticals